Signant Health Acquires Ametris to Create an End-to-End eCOA and Digital Outcome Measures Platform

Signant Health has announced its acquisition of Ametris, a global digital health solutions provider, for an undisclosed amount. The transaction, which took place on May 14, 2026, aims to create a comprehensive platform that integrates patient-reported outcomes with wearable-derived digital outcome measures. This strategic move is expected to enhance the capabilities of both companies in the clinical trial sector by simplifying the management of multimodal studies and accelerating insights for sponsors.

Ametris, formerly known as ActiGraph, has been a key player in the digital health space for over two decades, focusing on transforming real-world patient data into validated clinical evidence. The company has developed regulatory-aligned wearable-derived measures of physical activity and function, which are captured in patients' natural environments. By joining forces with Signant Health, Ametris aims to further its vision of integrated multimodal evidence generation, leveraging Signant's leadership in clinical outcome assessments (COA) alongside its own strengths in sensor-based measurement.

The acquisition is particularly significant in the context of evolving clinical trial methodologies that increasingly require multiple lines of evidence to demonstrate meaningful treatment benefits. Sponsors are under pressure to provide compelling regulatory cases that encompass both the patient voice and objective outcome measures. The integration of Ametris' eCOA solutions with wearable-derived data will allow Signant Health to offer a single provider solution, streamlining vendor management and reducing the complexities associated with reconciling disparate datasets.

In the near term, the combined company plans to focus on unified data flows and workflows, coordinated deployment tools, and integrated analytics. This strategic alignment is expected to enhance the efficiency of clinical trials, enabling sponsors to build stronger evidence packages. Additionally, the collaboration opens avenues for the development of AI and machine learning algorithms that can identify patterns across both patient-reported and sensor-derived data, potentially leading to novel digital and composite outcome measures.

The broader implications of this acquisition reflect a growing trend in the clinical trial sector towards integrated solutions that enhance data quality and accessibility. As the demand for comprehensive evidence generation continues to rise, the partnership between Signant Health and Ametris positions them to be at the forefront of innovation in clinical trials. This merger not only strengthens their market presence but also aligns with the industry's shift towards more patient-centric approaches in clinical research, ultimately benefiting sponsors and patients alike.